<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01292824</url>
  </required_header>
  <id_info>
    <org_study_id>RG_10-104</org_study_id>
    <secondary_id>2010-020358-32</secondary_id>
    <nct_id>NCT01292824</nct_id>
  </id_info>
  <brief_title>Pilot Study of Hepatitis C Virus Entry Inhibitor (ITX 5061) in Liver Transplant Recipients</brief_title>
  <acronym>ITX5061</acronym>
  <official_title>Phase I Study of Hepatitis C Virus (HCV) Entry Inhibitor (ITX 5061) in Liver Transplant Recipients With HCV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I pilot study to determine the safety and preliminary efficacy of a novel
      hepatitis C virus (HCV) entry inhibitor (ITX 5061) in patients with HCV infection undergoing
      liver transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis C virus (HCV) infection is common and treatment options at present are limited.
      Recurrence of HCV infection after liver transplantation is inevitable and disease progression
      is rapid when compared with disease in the non-transplanted liver.

      Studies of ITX 5061 in vitro have shown it to be a potent inhibitor of HCV entry into
      hepatocytes, through blocking the interaction of the virus with scavenger receptor BI
      suggesting it may reduce graft re-infection rates after liver transplant.

      There are no studies of treatments to block host receptors for HCV and the investigators
      hypothesize that ITX 5061 will modulate HCV kinetics in the early phase post liver
      transplant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety of ITX 5061 in liver transplant recipients</measure>
    <time_frame>90 days</time_frame>
    <description>Safety will be assessed by determination of the frequency of:
perioperative events: including transfusion requirements and vasopressor requirements
post-operative events: including primary graft non-function, hepatic artery thrombosis, acute cellular rejection and infective complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine whether treatment leads to an alteration in HCV RNA kinetics in the first week after liver transplantation</measure>
    <time_frame>One week</time_frame>
    <description>Hepatitis C virus titers will be measured at multiple times in the peri- and immediate post-operative period and kinetics assessed at 7 days after liver transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine whether any change in early viral kinetics is sustained</measure>
    <time_frame>90 days</time_frame>
    <description>Hepatitis C virus titers will be measured at multiple times in the post-operative period and kinetics assessed at 90 days after liver transplant.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Evidence of Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Standard liver transplant care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Liver Transplantation as per Standard of Care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ITX 5061</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liver Transplantation as per Standard of Care + ITX5061</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ITX 5061</intervention_name>
    <description>ITX 5061 (150mg) pre-transplant, immediately post-transplant and daily thereafter for 1 week.</description>
    <arm_group_label>ITX 5061</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old, ≤ 65 years old

          -  Plasma HCV RNA positive at time of listing for liver transplantation

          -  Accepted for liver transplantation for any of:

          -  End-stage liver disease due to HCV infection

          -  End-stage liver disease due to HCV infection and alcohol related liver disease (ALD)

          -  HCC due to HCV

        Exclusion Criteria:

          -  Refusal or inability to give informed consent

          -  Viral co-infection with either hepatitis B virus (HBV) or human immunodeficiency virus
             (HIV)

          -  Pregnancy or breastfeeding

          -  Women, of child-bearing potential, who are not willing to practice effective
             contraception

          -  Men, sexually active with women of child-bearing potential, who are not willing to
             practice effective contraception

          -  Any situation that in the Investigator's opinion may interfere with optimal study
             participation

          -  Participation in any clinical study of an investigational agent within 30 days of
             recruitment

          -  Transplantation with a donor organ from a HCV positive individual
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J Mutimer, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Syder AJ, Lee H, Zeisel MB, Grove J, Soulier E, Macdonald J, Chow S, Chang J, Baumert TF, McKeating JA, McKelvy J, Wong-Staal F. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol. 2011 Jan;54(1):48-55. doi: 10.1016/j.jhep.2010.06.024. Epub 2010 Aug 21.</citation>
    <PMID>20932595</PMID>
  </reference>
  <results_reference>
    <citation>Rowe IA, Tully DC, Armstrong MJ, Parker R, Guo K, Barton D, Morse GD, Venuto CS, Ogilvie CB, Hedegaard DL, McKelvy JF, Wong-Staal F, Allen TM, Balfe P, McKeating JA, Mutimer DJ. Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation. Liver Transpl. 2016 Mar;22(3):287-97. doi: 10.1002/lt.24349.</citation>
    <PMID>26437376</PMID>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2011</study_first_submitted>
  <study_first_submitted_qc>February 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2011</study_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C virus</keyword>
  <keyword>Entry</keyword>
  <keyword>Scavenger receptor-BI</keyword>
  <keyword>High density lipoprotein</keyword>
  <keyword>Liver transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

